Author Description

The latest, most accurate prescription drug data - always at your fingertips New medicines, new drug interaction data, the most recent side effects findings, and certain drugs now removed from the market make it absolutely critical that you keep up-to-date with the very latest prescription drug information. Not only are today's prescription drugs vital to the patient's well-being, but their effectiveness and safety can impact the integrity and security of all professionals as well. In today's fast-moving healthcare field it's vital you keep up-to-date on: · the newest drugs - which drugs are indicated for the diagnosed condition · how different drugs interact · latest findings on side effects caused by the prescribed drug · recommended dosages · clinical pharmacology · pediatric use · contraindications · FDA use-in-pregnancy ratings · and much more The 2001 PDR® guarantees you the security of having up-to-the-minute, FDA-approved information on over 4,000 prescription drugs and important data on more than 250 drug manufacturers. Our new format allows dramatically improved readability and easier access to the information you need now. Among the new drugs featured in this edition: Relenza and Tamiflu are two new products that inhibit the influenza virus; Tequin and Avelox are two new broad-spectrum fluoroquinolone antibacterial agents; Synercid I.V. is the first antibacterial agent in the new streptogramin class of antibiotics; Celebrex, a COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID), is now indicated to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP); Protonix is a new proton pump inhibitor indicated for erosive esophagitis associated with GERD; Exelon is a new reversible cholinesterase inhibitor indicated for the treatment of Alzheimer's dementia; Zyvox is a new synthetic antibacterial agent of the oxazolidinone class; new safety information regarding Norvir concomitantly used with St. Joh